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DNA damage responses are the basis for conventional cancer treatments like γ-
irradiation and chemotherapy, and the p53 protein is a key mediator in this process. 
Our lab has recently demonstrated that elevation of intracellular cAMP also leads to 
inhibition of DNA damage-induced apoptosis, and results so far have shown that this 
inhibition is mediated by downregulation of p53 at the level of protein stabilisation 
(Hallan Naderi et al., manuscript in preparation). 
 
Epstein-Barr virus is a DNA tumour virus implicated in the development of 
mononucleosis and cancers like Burkitt’s lymphoma, Hodgkin's lymphoma, gastric 
cancer, and nasopharyngeal carcinoma. We have recently shown in our lab that  
EBV-infection of B-cells inhibits the antiproliferative effect of cAMP (Kloster et al., 
manuscript in preparation).  
 
The aims of the present project were to unravel whether EBV-infection of B-cells 
prevents cAMP-mediated inhibition of DNA damage-induced apoptosis triggered by  
γ-radiation, and if so, to establish the mechanisms involved. Our experiments showed 
that EBV-transformed B-cells were more resistant to γ-radiation, and that EBV-
infection indeed prevents cAMP-mediated inhibition of apoptosis induced by ionizing 
radiation. Thus, we revealed that the stability of p53 in EBV-infected B cells was 
largely unaffected by cAMP, whereas the stability of p53 in control cells was reduced.  
Our analysis of the mechanisms involved in the ability of EBV to prevent cAMP-
mediated destabilization of p53 revealed that activation of Chk1 and Chk2 were 
unaffected, suggesting that the inhibitory effect of EBV on cAMP-mediated 
regulation of DNA damage-induced apoptosis is not mediated via checkpoint-control 

























AIDS    Aquired immune deficiency syndrome 
AMP    Adenosine monophosphate 
APAF-1   Apoptotic protease activationg factor-1 
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ATP    Adenosine triphosphate 
BART    Non-polyadenylated (non-coding) RNA 
BCR    B-cell receptor 
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BID    BH3-interacting-domain death agonist 
Bis    N,N-methylenebisacrylamide 
cAMP    Cyclic adenosine monophosphate 
CAK    Cdk-activating kinase 
Cdk    Cyclin dependent kinase 
Chk2    Checkpoint kinase 2 
CKI    Cyclin dependent kinase inhibitor 
COP-1    Coat protein complex 1 
dH2O    Distilled water 
EBER    Non-polyadenylated (non-coding) RNA 
EBNA    EBV-nuclear antigen 
EBV    Epstein-Barr virus 
EDTA    Ethylene diamine tetra acetic acid 
Epac1 & 2   Extracellular signal-regulated kinase 
FACS    Fluorescence activated cell sorter 
FADD    FAS-associated death domain 
FBS    Fetal bovine serum 
FDC    Follicular dendritic cell  
GADD45   Growth arrest and DNA damage 45 
HAUSP   Herpes virus associated ubiquitin-specific protease 
HD    Hodgkins lymphoma 
HIV    Human immunodeficiency virus 
HRP    Horseradish peroxidase 
HRS    Reed-Sternberg cells 
Ig    Immunoglobulin 
IM    Infectious mononucleosis 
INK4    Inhibitor of Cdk4 
LCL    Latently infected lymphoblastoid cell line 
LMP    Latent membrane protein 
MDM2   Murine double minute 2 
MOMP   Mitochondrial outer membrane permeabilization 






PBS    Phosphate buffered saline solution 
PCNA    Proliferating cell nuclear antigen 
PDA    Phosphodiesterase 
PI    Propidium iodide 
PKA    cAMP-dependent protein kinase 
pRB    Retinoblastoma protein 
RB    Retinoblastoma gene 
RB2    Retinoblastoma-like 2 
PTLD    Post-transplant lymphoproliferative disease  
rNTP    Ribonucleoside triphosphate   
SDS    Sodium dodecyl sulphate 
SDS-PAGE   SDS-polyacrylamide gel electrophoresis  
SMH    Somatic hypermutation 
TEMED   N,N,N’,N’-tetramethylethylenediamine  
TNF    Tumour necrosis factor 
TNFR1   Tumour necrosis factor receptor-1 
TRADD   TNFR1-associated death domain 
UV    Ultra violet 
V    Volt 
8-CPT-cAMP   8- ( 4- Chlorophenylthio ) adenosine- 3', 5'- cAMP                  
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1. INTRODUCTION 
 
1.1 The Cell cycle 
 
A cell reproduces by performing an orderly sequence of events in which it duplicates 
its contents and then divides into two daughter cells. This cycle of duplication and 
division, called the cell cycle, is the essential mechanism by which all living 
organisms reproduce. The details of the cell cycle vary from organism to organism 
and at different times in the organism’s life. However, certain characteristics are 
universal. The cell cycle is defined as the period between two cell divisions, and the 
eukaryotic cell cycle is traditionally divided into four sequential phases: G1, S, G2 
and M. Chromosome duplication occurs during S-phase of the cycle, whereas most 
other cell components are duplicated continuously throughout the cycle. The S- phase 
usually requires 10-12 hours, and occupies about half of the cell cycle in mammalian 
cells. In M-phase the duplicated chromosomes are segregated into individual nuclei 
(mitosis), and the cell splits in two (cytokinesis). The M-phase requires much less 
time, estimated to be less than one hour in mammalian cells. The S-phase and M-
phase are usually separated by gap phases, G1 and G2. In this way the cell is able to 
grow as well as monitor the internal and external environment to ensure that 
conditions are suitable and that preparations are complete before the cell commits 
itself to S-phase and mitosis. G1 is particularly important in this respect. G0 (zero) is 












1.1.1 Cell cycle machinery 
 
There are two key components in the cell cycle machinery; cyclins and cyclin-
dependent kinases (Cdks). If the Cdks are not tightly bound to a cyclin in a cyclin-
Cdk complex they have no protein kinase activity. Cdk levels are constant throughout 
the cell cycle, while cyclin levels undergo a cycle of synthesis and degradation. 
Therefore, cyclical changes in cyclin levels result in the cyclic assembly and 
activation of the cyclin-Cdk complex, which again trigger cell cycle events. 
Expressions of cyclins A and B are regulated periodically, whereas expression of 
cyclin D, and to a certain extent, cyclin E, is induced by mitogen stimulation. 
There are four classes of cyclins. G1/S cyclins (cyclin E) binds Cdk2 at the end of G1 
to commit the cell to DNA replication, S cyclins (cyclin A), binds Cdk2 during S-
phase and are required for initiation of DNA replication. M cyclins (cyclin B), bind to 
Cdk1 to promote the events of mitosis. In most cells, a fourth class of cyclins, G1 
cyclins (Cyclin D1, D2 and D3), helps promote passage through the restriction point 
(R) in late G1 by binding to Cdk 4 or 6. 






Figure 2: The fluctuation of cyclins and p27
(Kip1) 
during the cell cycle. Cyclin E, A and B is 
expressed periodically, whereas D-type cyclins are expressed in response to mitogen stimulation. 
p27
(Kip1)
 levels are high in quiescent cells, fall in response to mitogen stimulation and remain low in 
proliferating cells (Sherr, 1996). 
 
In absence of cyclin, the active site in the Cdk protein is blocked by a slab of protein. 
Cyclin binding causes this slab to move away, resulting in only part activation of the 
Cdk enzyme. Full activation occurs when a Cdk-activating kinase (CAK) 
phosphorylates an amino acid near the entrance of the active site, causing a small 
conformational change that further increase the Cdk activity. The activity of the 
cyclin-Cdk complex can be inhibited by phosphorylation at a pair of amino acids in 
the roof of the active site by a protein kinase known as Wee1, while 
dephosphorylation of these sites by a phosphatase known as cdc25 increases the 
activity. Cyclin-Cdk complexes can also be regulated by the binding of Cdk inhibitory 
proteins (CKIs) (for review see (Sherr & Roberts 1999)). These act primarily in the 
control of G1- and S-phase. There are two distinct families of CKIs; the INK4 
(inhibitor of Cdk4) family of proteins and the CIP/KIP family.  
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that primarily interact with cyclin-Cdk2 complexes. The G1- phase of the cell 
cycle is the most regulated phase (Boonstra 2003; Deshpande et al.), since it contains 
the R point. This point is located at the end of the G1-phase, where the cell has to 
decide whether to proceed through the cell cycle and undergo cell division, or to exit 
the cycle and go to G0 (Pardee 1974). The control of G1- to S-phase progression is 
often disrupted in cancer, leading to unrestrained cell-cycle entry and cell 
proliferation.  
 
1.1.2 The regulation of the R-point (G1-to S-phase transition): The Rb pathway 
 
The best understood effects of G1-Cdk activity in animal cells are mediated by a gene 
regulatory protein called E2F. It binds to specific DNA sequences in the promoters of 
many genes that encode proteins required for S-phase entry. E2F function is 
controlled primarily by an interaction with the retinoblastoma protein (pRb), an 
inhibitor of cell cycle progression. The retinoblastoma gene (Rb) was the first tumour 
suppressor to be identified. The Rb gene product, pRb, is thought to be one of the 
most important proteins in G1/S-phase transition, as it has a crucial role in the control 
of the R point in G1. During G1, pRb binds to E2F and blocks the transcription of S-
phase genes. In quiescent cells (G0), pRb is unphosphorylated. In cycling cells it has 
two phosphorylation forms; hypophosphorylated and hyperphosphorylated (Ezhevsky 
et al. 2001). pRb is sequentially phosphorylated throughout the cell-cycle by several 
cyclin-Cdk complexes. This is also terminated ‘the Rb pathway’. When cells are 
stimulated by extracellular growth signals, active cyclinD-Cdk4/6 and later cyclin E-
Cdk2 accumulates and phosphorylates Rb, sequentially reducing its affinity for E2F, 
allowing E2F to activate S-phase gene expression.  
 
 
Figure 3: The Mammalian cell cycle (see text for explanation). P indicates phosphate groups. 
INK4/Cip indicates the INK4 and CIP family of Cdk-inihibitory proteins (CKIs).  
 1.2 p53 pathway 
 
p53 is a tumoursupressor gene, and it is reported mutated in more then 50% of human 
cancers evidencing its role in tumourigenesis. The p53 protein was first described in 
1979 when it was found to complex with SV40 large T antigen (Lane and Crawford, 
1979; Linzer and Levine, 1979). Its overexpression seemed to cause oncogentic 
transformation of cells. This misled the first investigators to regard p53 as a tumour 
antigen or an oncogene. Later, when wild-type p53 was found, the true nature of p53 
was revealed. Wild-type p53 was often found inactivated in human tumour cells, and, 
when introduced into cells, it acted as a growth suppressor rather than an oncogene 
(Finlay et al., 1989). From the late 1980’s, p53 was therefore considered a tumour 





AD: Activation domain, 
DBD: DNA binding domain 
PRD: Proline rich domain, 
NLS: Nuclear localization signal 
TD: Tetramerisation domain 
BD: Basic domain 
  




P53 is a nuclear transcription factor of 53 k Dalton. It activates the transcription of 
several target genes involved in cell growth and apoptosis. The protein consists of 339 
amino acid residues, devided into four structurally and functionally different domains. 
The acidic amino terminal consists of the first 42 amino acids, and is responsible for 
the transactivating properties of the protein. Without this domain, the induction of 
target genes cannot occur. Interaction with MDM-2 also occurs at this domain. Amino 
acids ranging from 102 to 292 form the central sequence-specific DNA-binding 
domain. This is the most common location of p53 mutations. Between these, a novel 
proline rich domain has been identified. The carboxy-terminal domain displays many 















In broad terms, a wide variety of intrinsic and extrinsic stress signals engage the p53 
network, resulting in marked accumulation and activation of the p53 protein. These 
signals all impact upon the cellular homeostatic mechanisms that monitor and control 
the fidelity of DNA replication, chromosome segregation and cell division. Among 
the stresses that activate p53 is damage to the DNA by γ – or UV irradiation, 
alkylation of bases, DNA cross-linking, depurination of DNA, reaction with oxidative 
free radicals, alteration of the deoxyribose sugar moiety and by other stress signals 
like spindle damage, hypoxia, nutrition deprivation, nitric oxide in inflammation, 
heat/cold shock and rNTP (Ribonucleoside triphosphate) depletion (for review see 
Levine et al. 2006). This large number of diverse cellular stress signals is fed into only 
a central, single node for monitoring, i.e. p53. The advantage of this arrangement is 
that one entity can act as an efficient integrator of information about all the different 
types of stress that can act upon the cell. On the other hand, giving a single gene and 
its product such a crucial role also makes the system vulnerable. Most cancers appear 
to induce loss of function of the p53 pathway, or as a result of mutations of genes that 
encode proteins that act upon p53 (Royds and Lacopetta, 2006).  
 
The activation of p53 that occurs in response to stress signals can be defined as an 
increase in concentration of the p53 protein, and an increased activity of a p53 protein 
for transcription of a set of genes that have a p53 response element in their promotors. 
The levels of p53 are regulated mainly by its proteolytic turnover, and under normal 
conditions the protein has a short half-life of approximately 6-20 min. This is due to 
an E3 ubiquitin ligase known as MDM-2 (murine double minute 2). Under normal 
conditions MDM-2 monoubiquinates the p53 protein, exports it from the nucleus into 
the cytoplasm where it is ployubiquinated and degraded by the 20S proteasome. The 
exact mechanism of stabilization of p53 remains unclear, but it involves a series of 
post-translational modifications to both itself and MDM2 which facilitate dissociation 
of the p53-MDM2 complex (for review, see Lavin and Gueven, 2006). It is evident 
that multiple other proteins also influence p53 stability. Recently, two other ubiquitin 
ligases were shown to act upon the p53 protein, COP-1 (Coat protein complex 1) and 
PIRH-2 (Leng et al., 2003; Dornan et al., 2004). MDM2 is also capable of self 
ubiquination. Exposure of cells to stress reduces sumoylation of MDM2 and causes an 
increase in self-ubiquitination and degradation, thus favouring p53 stabilization.  
There is also evidence that post-translational modification of the MDM2 protein 
destabilizes its interaction with p53 and therefore contributes to p53 stabilization in 
response to stress. Studies have revealed that ATM phosphorylates MDM2 on Ser 395 
in response to double strand DNA breaks, making it less capable of exporting p53 
from the nucleus, suggesting the phosphorylation destabilizes p53-MDM2 interaction 
(Maya et al., 2001). ATM can also phosphorylate p53 directly on Ser15, and 
indirectly on Ser20 via Chk2 and thereby contribute to its stabilisation.  
 
Another protein, MDMX, inhibits the transactivation activity of p53 (Marine et al., 
2005). MDM2 and MDMX interact to protect p53 from MDM2 mediated degradation. 
This is achieved by prevention of nuclear transport by MDMX. On the other hand, 
MDMX stabilizes MDM2 by preventing its self-ubiquination. MDM2 and MDMX are 
functionally dependent in controlling p53. In absence of MDMX, MDM2 have a 
shorter half life and reduced capacity to control p53, while MDMX is dependent on its 
binding to MDM2 to enter the nucleus to inhibit p53 function. In addition, it has 
recently shown that ATM-dependent phosphorylation of both MDM2 and MDMX 
lowers their affinity for the deubiquitinating enzyme herpes virus associated 
ubiquitin-specific protease (HAUSP), resulting in decreased activity and stability of 








































































Figure 5: p53-mdm2 interaction under none-stress and stress conditions (see text for 
explanation).P indicates phosphate groups. 26S indicates proteolysis in the 26S proteasome. U 
indicates ubiquitin groups. DSB indicates DNA double strand breaks. Self-ub indicates self- 
ubiquination.  
In addition to be regulated at the level of stability, the action of p53 can also be post-
translationally mediated in response to stress signals. Thus, both the N-and C-terminal 
of p53 can be modified by phosphorylation, acetylation, methylation, ubiqitination 
and sumoylation. Clearly, the whole process of p53 activation is complicated and fine 
tuned to ensure that the protein is only activated with the appropriate response.  
Several studies have suggested additional levels of the control of p53 protein, both at 
the transcriptional and the translational level, forming the basis of future research (for 
review, see Levine et al., 2006).  
 
Once activated, p53 transcribes a number of genes that can be either stress- or tissue 
specific. MDM2 is one of them, causing alternating oscillating levels of p53 and 
MDM2 in the cell. There are three primary responses to a stress input signal by the 
p53 pathway; cell cycle arrest, apoptosis or cellular senescence. The way p53 brings 
about cellular senescence is not fully established, but one of the target genes of p53 




 is phosphorylated and activated by p53 in 
response to cellular stress, and p21
(Cip1)
 will in turn inhibit Cdk4/Cyclin D that 
normally phosphorylates pRB causing it do dissociate from E2F and thus inhibit the 
transcription of S-phase genes required for G1-S transition. p21
(Cip1)
 also inhibits 
Cdk2/Cyclin E, to maintain the G1/S arrest. There is some controversy concerning 
whether p53 mediates G2 arrest. Another transcription product of p53 induced by 
DNA damage and some other stress signals is GADD45 (Growth arrest and DNA 
damage). GADD45 is a nuclear protein postulated to take part in both cell cycle arrest 
and DNA repair. Stabilized p53 also increases the expression of numerous pro-
apoptotic genes (BAX, NOXA, PUMA etc) causing damaged cells to undergo 
apoptosis, and recently it has also been revealed that p53 has extranuclear apoptotic 
functions independent of transcription. Thus, p53 binds the anti-apoptotic BCL-2 
proteins (Bcl-2 and Bcl-x) and activates the pro-apoptotic multi domain proteins (Bax 
and Bak) to induce mitochondrial outer membrane permeability (MOMP), 
cytochrome C release and subsequent apoptosis. Cells that have engaged p53-
dependent apoptosis typically follow the intrinsic cell death pathway (see below), but 
it is also demonstrated that p53 can promote Fas-mediated (extrinsic) apoptosis by 
increasing the expression of Fas (Liu et al., 2006). 
DNA damage                     
 
                                         MDM2 
 
p53   
 
         p21(Cip1/Waf1)                                GADD45                        BAX, NOXA, 
PUMA
    
 
 
Cell cycle arrest                     DNA repair                             Apoptosis 
Figure 6: A simplified cartoon of p53 responses to DNA damage. Thin dashed arrow: transcription 
independent p53 mediated apoptosis. 
 
 1.3 Apoptosis  
 
In general, cells die through one of two different pathways; necrosis or apoptosis. 
Necrosis is a passive and unregulated form of cell death caused either by stimuli that 
damage the cell membrane directly or by inhibition of the energy production in the 
cell (Endresen and Aarbakke, 1992). The necrotic cell swells, bursts and cell content 
leaks out causing inflammation in the surrounding tissue. Kerr and co-workers made 
the discovery of a form of cell death that was distinctly different from necrotic cell 
death occurring under pathological conditions (Kerr et al., 1972). In multicellular 
organisms, cells that are no longer needed or are a threat to the organism are 
destroyed by a tightly regulated cell suicide process known as programmed cell death 
or apoptosis. Apoptosis is a physiological from of cell death responsible for balancing 
the continuous renewal of the cells in the body and disturbances in the regulation of 
this process may be of importance in developing of diseases such as cancer, immune 
system disorders or neurodegenerative diseases. 
The characteristics of apoptosis are cell shrinkage, chromosome condensation, 
fragmentation of DNA into 200bp fragments, and phagocytosis of the apoptotic cell. 
The process requires ATP, and no inflammation is induced in the surrounding tissues. 
The reason for this is that the membrane is never disrupted during apoptosis, and that 
apoptotic cells are recognized and phagocyted by macrophages. 
 
There are two signalling pathways that trigger apoptosis (Chipuk and Green 2005). 
The intrinsic pathway is engaged by cellular stresses such as DNA damage, hypoxia 
or growth factor withdrawal. It directly impacts on the Bcl-2 family of proteins by 
transcriptional induction, repression or post-transcriptional modifications that act to 
repress or enhance function. The  Bcl-proteins, Bax and Bak, then elicit mitochondrial 
outer membrane permabilization (MOMP), cytochrome c release and APAF-1 
(apoptotic protease activating factor 1)-dependent pro-caspase-9 activation. Caspase-
9-dependent cleavage then activates executioner caspases-3 and -7 responsible for the 
apoptotic hallmarks such as chromatin condensation, plasma membrane asymmetry 
and cellular blebbing. The Bcl-2 protein itself is also located in the outer 
mitochondrial membrane, and this protein forms complex with Bax or Bak to inhibit 
cytochrome C release and apoptosis. 
 
The extrinsic pathway requires the ligation of death receptors by death ligands. For 
example, tumour necrosis factor (TNF) binds to its death receptor, TNFR1 which 
causes the recruitment of adaptor molecules, TRADD (TNFR1-assosiated death 
domain) and FADD (FAS-assosiated death domain). This causes pro-caspase-8 
recruitment and activation. Executioner caspases-3 and -7 are then activated by 
caspase-8, resulting in cell death. Caspase-8 can also cleave and activate BID (BH3-

























1.5 DNA damage caused by ionizing radiation 
 
DNA damage is common in the life of a cell, and might lead to mutations, cancer, and 
cellular death. Damage to DNA induces several cellular responses that include: (a) 
removal of damage and restoration of the continuity of the DNA duplex; (b) activation 
of DNA damage checkpoints which arrests cell cycle and thereby allows the cell to 
repair the damage, and thus prevents the transmission of damaged or incompletely 
replicated chromosomes; (c) transcriptional response; and (d) apoptosis, which 
eliminates heavily damaged or deregulated cells. Defects in any of these processes 
may cause genomic instability (Sancar et. al, 2004). DNA damage checkpoints are 
biochemical pathways that delay or arrest cell cycle progression in response to DNA 
damage. These pathways are operative under normal growth conditions, and are 
amplified upon an increase in DNA damage. Whether there is a threshold for the 
amount of damage necessary to induce a checkpoint response is not known. The term 
checkpoint is defined, based upon the interstate transition that is being inhibited by 
DNA damage, as G1/S, intra-S and G2/M checkpoint.  
 If the DNA damage is double strand breaks caused by ionizing radiation, ATM (ataxia 
teleangiactasia mutated) is activated, functioning as a checkpoint sensor. Mutations in 
this gene can cause ataxia-teleangiectasia (A-T), a condition characterized by 
cerebellar degeneration, immunodeficiency, genome instability, clinical 
radiosensitivity and cancer predisposition, indicating a central role in regulation of 
cell proliferation. When activated, ATM phosphorylates many proteins, including 
Chk2 (Thr68), p53 (Ser20) and itself. These phosphorylations result in two signal 
transduction pathways, one to initiate and one to maintain G1/S-phase arrest. The 
initiating process is phosphorylating of Chk2, which in turn phosphorylates Cdc25 
phosphatase, causing its deactivation by nuclear exclusion and ubiquitin-dependent 
proteolytic degradation. This results in the accumulation of the phosphorylated, 
inactive form of Cdk incapable of phosphorylating Cdc45 to initiate replication. This 
rapid response is followed by the p53 mediated maintenance of G1/S arrest.  
 
ATM directly phosphorylates Ser15 of p53 and Ser20 indirectly via Chk2. This 
phosphorylation inhibits the nuclear export and degradation of p53, resulting in 
increased levels of p53. p53 then activates its target genes, including the Cdk inhibitor 
p21
(Cip1)
, which inhibits transcription of S-phase genes as described for “The RB 
pathway”. This results in maintenance of the G1/S arrest. In addition to cell cycle 
arrest, ionizing radiation damaging cells beyond repair may also lead to their 
elimination by p53-mediated apoptosis (see above).  Loss of either of these functions 
could contribute to tumorigenesis. Cells that fail to arrest in G1 after DNA damage are 
more likely to propagate mutations, and in the absence of p53, damaged cells may not 





















Figure 8: DNA-damage response.  
 
1.5 cAMP/PKA pathway  
 
The second messenger concept of signalling was born with the discovery of cyclic 
adenosine monophosphate (cAMP) and its ability to influence metabolism, cell shape 
and gene transcription via reversible protein phosphorylations. cAMP was first 
identified as a small intracellular mediator in the 1950s. Since then, it has been found 
to act in this role in all prokaryotic and animal cells studied. cAMP is synthesized 
from adenosine-triphosphate (ATP) by a plasma-membrane-bound enzyme named 
adenylyl cyclase (AC) that removes two phosphate groups as pyrophosphate. cAMP is 
unstable in the cell because it is rapidly and continuously destroyed by one or more 
cyclic AMP phosphodiesterases (PDA) that hydrolyze cAMP to adenosine 5’-
monophosphate (5’-AMP). Extracellular signals such as hormones, growth factors and 
neurotransmitters can therefore by inducing rapid synthesis and removal of cAMP 
cause levels in the cell to change by more than twenty fold in seconds. 
 
All receptors that act via cAMP are coupled to a stimulatory G protein, which activate 
AC and thereby increase cAMP concentration. It was long thought that the only target 
of cAMP in the cell was cAMP-dependent protein kinase (PKA). In recent years it has 
become clear that even though it mainly exerts its effects by this pathway, not all 
effects of cAMP in animal cells are mediated by general activation of PKA. At 
present, cAMP is known also to directly regulate ion channels and the ubiquitous Rap 
guanine exchange factors Epac1 and 2 (extracellular signal-regulated kinase) 
(Kopperud et al. 2003).  In inactive state, PKA in cytosol consists of a complex of two 
catalytic subunits and a regulatory subunit dimer to which cAMP can bind to (Corbin 
et al. 1978). Binding of cAMP to the regulatory subunits result in a conformational 
change, causing these subunits to dissociate from the catalytic subunits, and thus 
activating their catalytic kinase activity. The released catalytic subunits then move 
into the nucleus, where they phosphorylate gene regulatory proteins, while the 
regulatory subunit remains in the cytoplasm. The substrates for PKA differ in 




Figure 9: cAMP-PKA pathway. In order to activate PKA in cells we have used the two components 
forskolin and 8-CPT-cAMP.Forskolin is a deterpine compound isolated form plants, and it induces 
increased intracellular levels of cAMP by directly activating AC (Seamon & Daly 1981). 8-CPT-cAMP 
is a membrane permeable analogue of cAMP.      
 
1.5.1 cAMP and growth control 
  
cAMP exerts an antiproliferative effect on a number of cell types, including 
lymphocytes (Blomhoff et al. 1987), proposed to be mediated by its ability to inhibit 
G1/S transition. Evidence of a new mechanism whereby cAMP might inhibit cellular 
proliferation was recently provided by our group. It was shown that elevation of 
intracellular levels of cAMP inhibits DNA replication and arrests the cells in S-phase. 
This inhibition is associated with increased binding of p21
(Cip1)
 to Cdk2-cyclin 
complexes, inhibition of Cdk kinase activity, dephosphorylation of RB and 
dissociation of PCNA (proliferating cell nuclear antigen) from chromatin in S phase 





















1.6 The immune system 
 
The main purpose of the immune system is to protect the organism from infections. 
The immune response is divided in two; the innate (non-specific) and adaptive 
(specific) immune response. The innate immunity is the first line of defence against 
foreign agents. It is mediated by cellular elements, such as monocytes and 
macrophages, and components of the complement system. These components do not 
require previous exposure to foreign agents. The adaptive immunity is mediated via 
lymphocytes, and is characterized by specificity for antigen and immunological 
memory. T-lymphocytes are responsible for the cellular part of the specific immune 
response, whereas B-lymphocytes mediate humoral immunity through production of 
antibodies. The innate response is rapid, but can sometimes damage normal tissue due 
to lack of specificity. The adaptive immune response take several days or weeks to 
develop, but is precise and due to its immunological memory, subsequent responses 
are more vigorous and rapid. There are interaction between B-cells and T-cells both 
during development and activation of cells and during the adaptive immune response. 
 
1.6.1 B-cell development and response 
 
B-cell development takes place in the bone marrow. Here, gene segments encoding 
the variable (V) region of antibody molecules are assembled by somatic 
recombination. As a large number of gene segments (V,D,J) are available, each B-cell 
has a unique B-cell receptor (BCR) which represents a clonal marker. B-cells 
expressing a functional BCR are released into the periphery as mature, antigen-naive 
B-cells. If antigen is recognized by the naive B-cell, it will bind, and if T-cell help is 
available, initiate activation of the B-cells in the T-cell zone of lymphoid organs. 
Activated B-cells then migrate into B-cell follicles, start to proliferate and 
differentiate into centroblasts, and thereby establish germinal-centres. 
 
In the proliferating centroblasts the process of somatic hypermutation (SMH) in the V 
region genes is established, and thus generates new antibody variants. Centroblasts 
then differentiate into resting centrocytes, and only cells with acquired affinity-
increasing mutations of their BCR are able to interact with the germinal-centre T-cells 
and follicular dendritic cells (FDCs) and thereby receive survival-signals. The 
remaining undergo apoptosis. The selected germinal-centre B-cells then undergo 
repeated rounds of replication, mutation, and selection, and the immunoglobulin genes 
of many of the cells are also remodelled by class switching. 
Finally the selected germinal-centre B-cells differentiate into either memory B-cells 










1.6.2 The B-lymphoid cell line Reh  
 
A population of cells that is able to propagate indefinitely in culture is called a cell 
line. As normal B-lymphocytes have very limited lifespan in culture, cell lines derived 
from normal and malignant lymphocytes have become a valuable tool in research. In 
the experiments in this paper, the lymphoid cell line Reh was used as a control against 
EBV-transformed B-lymphocytes. This B-lymphoid line was established in 1974 from 
the blood of a 15-year old North African girl with acute lymphoblastic leukaemia 
(Rosenfeld et al, 1977). Like normal B-lymphocytes, the Reh cells express the CD19 
marker, and the cells are EBV-negative. 
 
1.7 Epstein- Barr virus 
 
Epstein- Barr virus (EBV) was the first candidate human tumour virus. It is a double 
stranded DNA virus genome of 172 kb, belonging to the γ herpes virus family. It 
mainly targets B-lymphocytes, but in some circumstances EBV also infects other 
cells, like T-cells or epithelial cells. The virus was first identified in 1964 from 
examining electron micrographs of cells cultured from Burkitt’s lymphoma (Epstein 
et al.1964).  EBV is the most successful human pathogen because it latently infects 
greater then 90% of the human population. Hosts are usually affected in early 
childhood as an asymptomatic infection. Like all herpes viruses, EBV is able to 
persist in the host for life, but in the majority of healthy carriers the virus causes no 
disease. This is because a delicate balance between the host immune system and the 
virus is maintained. Disruption of this balance may lead to the development of EBV-
associated disease. It therefore seems that EBV has the potential to be highly 
pathogenic yet rarely manifests this potential. Studies over the last several years show 
that this is because EBV has the unique ability to transform resting B-cells into 
permanent, latently infected lymphoblastoid cell lines (LCLs), and therefore persists 
in resting, non proliferating memory cells (Babcock et al., 1998).  
 
1.7.1 EBV latent genes and transformation 
 
In EBV-transformed LCLs, every cell carries multiple extrachromosomal copies of 
the viral episome and constitutively expresses a limited set of viral gene products. 
EBV transits the epithelium and infects naive B-cells in the underlying tissue, where it 
expresses a set of latent genes that causes the cell to become activated and proliferate 
as though it was responding to antigen.  This growth program/latency III consists of 
six EBV nuclear antigens (EBNAs 1,2,3A,3B and LP) and three latent membrane 
proteins (LMPs 1, 2A and 2B). These proteins have all the necessary activities to push 
the B-cell to become an activated blast without any external signalling (for review, 






Figure 11: The Epstein-Barr virus genome. Diagram showing the location of the EBV latent genes 
on the double stranded viral DNA episome. OriP indicates the origin of plasmid replication. TR 
indicates the terminal repeat region. EBNA indicates the latent EBV nuclear antigens. LMP indicates 
the latent membrane proteins. The blue arrow represents the highly transcribed non-polyadenylated 
RNAs EBER1 and 2. The long outer green arrow represents EBV transcription during latency III, 
always starting at the Cp or Wp promoter. The inner red arrow represents the EBNA1 transcript, which 
originates from the Qp promoter during latency I and II. Transcripts from the BamHIA region can be 
detected during latent infection, but no protein arising form this region has been definitively identified. 
The locations of the BARF 0 and 1 are also shown (Young and Rickinson, 2004).  
 
Once activated, the cell migrates to the follicle where the viral transcription program 
changes, so that only three latent proteins are expressed: EBNA1 (required to replicate 
viral DNA), LMP1 and LMP2 (the default program/latency II). LMP2 alone will push 
B-cells to form a germinal centre in the mucosal follicle. LMP1 and LMP 2 can drive 
immunological gene mutation and isotype switching, respectively, and LMP1 
downregulates the expression of bcl-6 (germinal centre regulatory transcription 
factor), the signal for a memory cell to exit the germinal centre. This implies a 
coordinated process in which LMP2 is turned on before LMP1 during the germinal 
centre reaction. Once in the periphery, the LCLs shut down all viral protein 
expression (EBNA1 only program/latency I), and appear to be maintained as normal 
memory B-cells (for a review, see Thorley-Lawson, 2006). 
 
Infectious mononucleosis (IM) is generally the result of delayed primary infection 
with EBV characterized by the triad of fever, lymphadenopathy and pharyngitis 
(Papesch & Watkins, 2001). These symptoms typically occur in young adults, but are 
occasionally seen in children and older adults. IM is rare in nonindustrial countries, 
where infection almost invariably occurs asymptomatic in early childhood. A classical 
feature of IM is blood lymphocytosis, consisting mainly of CD8+ T-cells, and this 
immune response is thought to cause the clinical symptoms. In the early stages of the 
acute infection, the number of LCLs in the blood reaches staggering proportions, with 
50% or more of memory cells being infected. Classic acute IM resolves in 2 to 6 
weeks, but relapses can occur in the first 6- 12 months, and IM may be linked with a 
prolonged fatigue syndrome and depression. After this time, the level of infected cells 
appears to be relatively stable over many years (for review see Williams & Crawford, 
2006). There are no longer viral proteins expressed that can cause the cell to divide, 
and because EBNA1 represents the only point of immune attack of the memory cells, 
it has evolved to be poorly recognized by the immune system (Levitskalya et al., 
1995).  
 
The EBV might promote the development of gastric cancer (Osato & Imai, 1996), 
nasopharyngeal carcinoma (Henle & Henle, 1976), and B-cell malignancies, including 
Burkitt’s lymphoma (Epstein et al., 1964), Hodgkin’s lymphoma (Deacon et al, 1993), 
post-transplant lymphoproliferative disease (Swinnen, L.J., 1999), and AIDS-
associated lymphomas. The origin of these tumours can be understood as arising from 
specific stages of the EBV life cycle, and appear to be associated with disturbances in 
the immune system. The first three types of B-cell malignancies have been studied 
most extensively, and will be discussed below. 
 
1.7.2 Burkitt’s lymphoma 
 
EBV was discovered in cultured tumour cells from patients with the endemic form of 
Burkitt’s lymphoma. The lymphoma was first described in children in equatorial 
Africa and New Guinea where malaria is holoendemic (Burkitt, 1962). EBV is present 
in all cases of ‘endemic’ lymphomas, in up to 85% of cases in areas with intermediate 
incidence, but only in 15% of the low-incidence sporadic tumours seen in children in 
the developed world. Burkitt’s lymphoma  is also common among adults with HIV, 
often arising as the first AIDS-defining illness in relatively immunocompetent 
patients. A hallmark of Burkitt’s lymphomas is the translocations of the proto-
oncogene MYC into one of the immunoglobulin loci, resulting in constitutive activity 
of this transcription factor. In addition, many tumours have mutations in the p53 gene 
or other defects in the p53-ARF pathway, as well as mutations in the putative tumour 
suppressor gene retinoblastoma-like 2(RB2).  Burkitt lymphoma cells phenotypically 
resemble centroblasts. Many lymphoma-cells also show evidence of active somatic 
hypermutation – and thereby support the suggestion that they originate in germinal 
centres (Klein et al., 1995).  Besides the EBERs and BARTs, only EBNA1 protein is 
expressed (latency I/EBNA1 only program). Its oncogenic potential is debated. 
Several findings indicate a possible role for the EBERs, but how EBV contributes to 
the pathogenesis of Burkitt’s lymphoma still remains a matter of speculation.  
 
 
1.7.3 Hodgkin’s lymphoma 
 
Acute EBV-infection in adolescent-adult can give rise to IM, long known to be a risk 
factor for Hodgkin’s lymphoma (HD). HD is characterized by atypical, large tumour 
cells known as Reed-Sternberg cells (HRS) (Küppers, 2002). These usually represent 
less than 1% of the tumour tissue, the rest is non-malignant T-cells, B-cells, 
eosinophils and others. There is a classical form of Hodgkin’s Lymphoma, accounting 
for 95% of cases, and a lymphocyte predominant form. The HRS of the latter is 
always EBV negative, whereas in 40% of the classical form in the western world EBV 
is detected. This can approach 80% in developing countries and up to 100% in AIDS-
related HD (for review, see Andersson, 2006) 
 
 In EBV-positive cases, three EBV proteins are expressed; EBNA1, LMP1 and 
LMP2A (latency II/default transcription programme). Single-cell molecular analysis 
showed that HRS cells, in nearly all cases derive from B-cells; less than 5% have T-
cell origin. The rearranged Ig V genes of HRS are somatically mutated, but lack 
intraclonal diversity, indicating that the SHM machinery is silenced in the tumour 
cells. In ~25% of cases, there are non-sense mutations or deleterious deletions in 
originally functional V gene arrangements. Normally, such ‘crippling’ mutations 
would sentence the B-cell to apoptotic destruction in the germinal centre, and 
therefore HRS cells presumably derive from pre-apoptotic germinal centre B-cells 
that were rescued from apoptosis by some transforming event (s). As a lot of other 
mutations can target a cell for apoptosis, it is postulated that the HRS cells lacking 
recognizable crippling mutations also derive from the pool of pre-apoptotic germinal-
centre B-cells with disadvantageous mutations. (Küppers, 2003). 
 
1.7.4 Post-transplant lymphoproliferative disease 
 
T-cell immunosuppressive therapy given to patients after transplantation renders 
patients susceptible to post-transplant lymphoproliferative diseases (PTLDs). Most 
PTDLs arise as polyclonal or monoclonal lesions within the first year after the 
procedure. These PTLDs are almost always of B-cell origin and EBV-positive, most 
likely because suppression of T-cell response allows uncontrolled proliferation of 
EBV-transformed B-cells. The majority expresses the latency III programme/Growth 
programme, but more restricted gene-expression patterns are also observed. 
Transplant cohorts continue to show a significant, albeit lower risk of proliferative 
disease well beyond the first year, but this represents a more heterogeneous group, 
and the number of EBV-associated cases can fall below 50%. Ig-gene sequencing 
show that PTLDs can arise from various stages of the B-cell differentiation pathway 






Figure 12: The putative checkpoints in the EBV life cycle that gives rise to tumours. The normal 
events in healthy carriers denoted in black. EBV infects naive B-cells in the Waldeyer’s ring, and these 
cells can differentiate into memory cells and out of the cell cycle, and are therefore not pathogenic. 
PTLD indicates post-transplant lymphoproliferative disease. If another cell than the naive B-cell in the 
Waldeyer ring becomes infected, it will express the latency III/growth program and continue to 
proliferate because it cannot differentiate out of the cell cycle (thin dashed lines). Normally these 
bystander B-cell blasts would be destroyed by CD8+ T-cells, but if the immune response is suppressed, 
they then can grow onto PTLD. A bystander B-cell could also arise if a latently infected germinal 
centre or memory cell fortuitously switched on the latency III/growth program. Hodgkin’s disease: 
arises from EBV-infected cells that are blocked at the germinal centre stage resulting constitutive 
expression of the default program/latency II. Burkitt’s lymphoma: evolves from germinal centre cells 
that are entering the memory cell compartment, but are stuck proliferating and consequently express 





































 2. AIMS OF THIS THESIS 
 
Previous work in our lab has shown that elevation of intracellular cAMP leads to G1 
arrest in normal and malignant lymphoid cells (Blomhoff et al., 1987), and recently it 
was also shown that elevation of intracellular levels of cAMP inhibits DNA 
replication and arrests the cells in S-phase (Naderi et al. 2005). 
 
Many anticancer agents that act via DNA damage-induced apoptosis (cytotoxic dugs 
and γ-irradiation) depend on DNA replication to exert their function and it could 
therefore be anticipated that elevation of cAMP would inhibit such DNA damage-
induced apoptosis. p53 is a tumour suppressor and an important downstream mediator 
of DNA damage responses. Upon DNA damage, p53 is stabilized and activated to 
induce transcription of genes involved in growth arrest, DNA repair and apoptosis. 
Our lab has recently demonstrated that elevation of intracellular cAMP indeed leads 
to inhibition of DNA damage induced apoptosis (Naderi et al., 2005), and our results 
so far have shown that cAMP inhibits DNA damage-induced apoptosis by 
downregulation of p53 at the level of protein stabilisation (Hallan Naderi et al., 
manuscript in preparation). 
 
Epstein-Barr virus is a DNA tumour virus belonging to the γ-herpes virus family. It 
can cause different types of cancer and proliferative disorders including Burkitt’s 
lymphoma (Epstein et al., 1964), nasopharyngeal carcinoma (Henle & Henle, 1976), 
gastric cancer (Osato & Imai, 1996), Hodgkin’s lymphoma (Deacon et al, 1993), and 
post-transplant lymphoproliferative diseases (Swinnen, 1999). Several years ago we 
showed in our lab that EBV-transformed B-cells no longer were inhibited by TGFβ 
(Blomhoff et al., 1987). The mechanism for this has later been described (For review, 
see Mori et al., 2003). Recently, we have shown that EBV- infection of normal B-
lymphocytes also abolishes the antiproliferative effect of cAMP in these cells, and it 
seems as though cAMP in EBV-transformed B-cells no longer can inhibit DNA 
replication (Kloster et al., manuscript in preparation). 
   
Since cAMP-mediated inhibition of DNA damage-induced apoptosis seems to be 
linked to inhibition of DNA replication and cAMP-mediated inhibition of DNA 
replication is reduced in EBV-transformed B-cells, we now have the following aims; 
 
 
1) To unravel whether EBV-infection of B-cells prevents cAMP-mediated 
inhibition of DNA damage-induced apoptosis triggered by γ-irradiation. 
  
 
2) To establish the mechanisms involved in EBV-mediated regulation of DNA 

















































Chemical     Producer 
 
Acidic acid     Merck 
Acrylamide/Bis    Sigma 
Ammonium persulphate   Shelton scientific 
Aprotinin     Sigma 
β-mercaptoethanol    Sigma 
β-glycerophosphate    Sigma 
Bio-Rad Protein assay   Bio-Rad 
Bromophenol blue    Bio-Rad 
Di-sodium hydrogen phosphate (NaH2PO4) Prolabo   
Fetal Bovine Serum    Gibco/BRL 
Forskolin     Calbiochem 
γ-globulin     Sigma 
Glycerol     Prolabo 
Glycine     Sigma 
HCl      Merck 
Isopropanol     Arcus 
Leupeptin     Sigma 
Methanol     BDH 
Molecular weight standard   Bio-Rad 
Non fat dried milk    Nestle 
Penicillin Streptomycin   Gibco/BRL 
PMSF      Sigma 
Ponceu S     Sigma 
Propidium Iodide    Sigma 
RPMI 1640     Gibco/BRL 
Sodium chloride (NaCl)   BDH laboratories 
Sodium deoxycholate    Sigma 
Sodium dodecyl sulphate (SDS)  Sigma 
Sodium Fluoride (NaF)   Merck 
Sodium orthovandate (Na3VO4)  Sigma 
TEMED     Bio-Rad 
Tris base     Angus Buffers & Biochemicals 
Triton X-100     Sigma 
Tween20     Sigma 
8CPT-cAMP     BIOLOG 









P53 total      Cell signalling 
P53 S15      Cell signalling 
P53 S20      Cell signalling 
Actin       Santa cruz 
Chk2 T68      Cell signalling 
Chk1 S317, S345     Cell signalling 
ATM       Rockland 
Goat-Anti-Mouse IgG     Bio-Rad  




ECL Western blotting analysis system  Amersham Pharmacia Biotech 




Beckman J2-21 centrifuge    Beckman 
Biofuge fresco table top centrifuge   Haraeus 
Cell culture flasks     NUNC 
Cell culturing plates (6-12-24 well)   BC;Falcon  
Centrifuge tube (15 and 50 ml)   Merck 
CO2-incubator                 Nuaire™ 
Coulter® Microdiff 18 (Cell counter)  Dan Meszantsky 
Eppendorf tubes (micro tubes 1,5 ml)  Axygen Scientific 
Erlenmeyer bottles     Pyrex 
FaCSCaliber      Becton Dickinson 
Falcon tubes (5ml)     Becton Dickinson 
Gamma-cell®3000 Elan    MDS Nordion    
Glacpack™      Andvord 
Heating block      Dan Meszantsky 
Hybond™ ECL™ Nitrocellulose membrane  Amersham Pharmacia Biotech 
Hyperfilm™ MP     Amersham Pharmacia Biotech 
Kodak X-Omatic cassette    Kodak 
Light microscope with 40x objective   Nikon 
ParafilmM      Kebolab 
Platform shaker     Edmund Blücker 
Rock-n-roller      Labinco 
Polystyrene Round-Bottom tube (5ml)  Falcon 
Rotator mixer      Stuart scientific 
Semicro disposable cuvettes (1,5ml)   Pharmacia Biotech 
Sigma 4K15 centrifuge    Sigma 
Spectrophotometer, Ultrospec 3000   Pharmacia Biotech 
Trans-Blot® SD Semi-Dry Transfer Cell  Bio Rad 
Water bath      Julabo 
Whatman® Chromatography paper 3 MM  Whatman 
3.2 Isolation and culturing of cells 
 
When isolating cells and keeping them in culture, it is important that all equipment 
used and all reagents in contact with the cells are sterile. This is accomplished by 
using an antiseptic technique at all times. In addition, antibiotics are added to prevent 
bacterial growth. The cells are grown in an incubator at 37 ˚C with 5% CO2 and 
humidified air to stimulate an in vivo situation. 
 
3.2.1 Isolation and EBV-transformation of B-lymphocytes 
 
Normal human lymphocytes are isolated from buffy-coats derived from volunteer 
blood donors at Ullevål University hospital. The erythrocytes and plasma are removed 
for clinical use, and what is left of the blood is called a buffy-coat. When studying B-
lymphocytes it is important to remove contaminating cells that can affect the 
functions of B-lymphocytes by cell-cell-contact or secretion of cytokines. B-cells are 
isolated from the buffy-coat by positive selection .This is done by using magnetic 
beads coated with antibodies against the CD19 antigen that is expressed on the surface 
of almost all B-cells, with the exception of plasma cells.  
 
EBV-transformation of B-lymphocytes is performed by resuspension of the isolated 
lymphocytes in RPMI medium and adding EBV supernatant from B 95/8 monkey 
cells and cyclosporine A. The medium is changed every third day for the first 14 days 
by removing 1 ml of old medium and replacing it with fresh medium containing 
cyclosporine A. After another week, the cells can be grown in culture flasks as other 
cells in suspension, and can be used in experiments. 
 
Since I did not isolate the B-cells of infect the cells with EBV myself, I will not 
explain these methods in detail. 
 
 
3.2.2. Culturing lymphoid cell lines and EBV-transformed B-cells. 
 
The lymphoid cell line Reh and the EBV-transformed B-cells are grown in complete 
RPMI medium. This medium contains inorganic salts, amino acids, vitamins, glucose, 
glutathione and pH-indicator. In addition there are growth factors that all cells need to 
grow and proliferate. The cells are cultured in 10% FBS. 
 
Equipment and solutions 
Complete RPMI medium  
Cell culture flask 
CO2  incubator 
 
 
RPMI medium with 10% FBS 
RPMI1640  500 ml 
Heat inactivated FBS   50 ml 
Penicillin 5000 IE/ml-      
Streptomycin 5 mg/ml    10 ml     





EBV-transformed human B-lymphocytes have a doubling time of approximately 36 
hours. The cell cultures are diluted so that the cell concentration is kept between 0,5 – 
1,0 x 10
6 
cells/ml. Reh cells have a doubling time of about 24 hours, and the optimum 
density of the cells is 0,15 – 1,5 x 10
6
 cells/ml. When used in experiments, Reh cells 
are split to 0,4 x 10
6 
cells/ml the day before use. Otherwise the cultures are split every 
2 or 3 days with RPMI medium. 
 
3.2.5 Cell counting 
 
Cells are counted in an automatic cell counter, Coulter® Microdiff 18 ,which counts 
cells by detecting and measuring changes in electrical resistance when a particle in a 
conductive liquid passes through a small aperture. As each cell passes, it impedes the 




3.3. Cell irradiation 
 
To induce DNA damage, the cells were exposed to γ-irradiation. 
 
Equipment and solutions 
Gamma-cell®3000 Elan    RPMI/PS/10 % FBS 
15 ml tubes     Cell culture flask    
  
12-well cell culture plate    CO2 incubator 
 
Procedure: 
The EBV- and Reh-cells were divided into smaller culture flasks (5- 10 ml), and 
exposed to ionizing radiation in the Gamma-cell®3000 Elan-apparatus. Reh-cells 
were treated with 10 Gy, and EBV-cells with 40 Gy. Following irradiation, the cells 
where incubated for another 4 hours at 37˚C . 0, 5 – 1 ml of each sample were then 
transferred to a 12 well culture plate, and incubated for 20 more hours before used in 
the Scatter/PI-analysis. The rest of the samples were used in the Western blot analysis 
after the initial 4 hours. 
 
3.4 Measuring cell death 
 
3.4.1 Scatter analysis 
 
This analysis is used to measure the distribution of viable and dead cells. A 
fluorescence activated cell sorter (FACS) measures and analyses optical properties of 
single cells passing through a focused laser beam. When cells pass through the laser 
beam, they disrupt and scatter the laser light, which is detected as forward scatter and 
side scatter. Forward scatter light is related to cell size while side scattered light is an 
indicator of the cell’s granularity. Apoptotic cells are smaller than viable cells, and 
more granular due to shrinkage of the cells, chromatin condensation, fragmentation of 
nuclei and the formation of apoptotic bodies. Necrotic cells will be larger than viable 
cells due to swelling. Thus, by this method it is possible to separate cells into viable 
cells, apoptotic cells and necrotic cells.  
3.4.2 PI-staining of cells 
 
By staining cells with Propidium iodide (PI) it is possible to distinguish between dead 
and viable cells. PI is a DNA-binding dye taken up by necrotic and late apoptotic 
cells. Viable and early apoptotic cells exclude PI because they have an intact nuclei 
membrane. PI-staining of the cells is detected as red fluorescence in a flow cytometer 
equipped with an argon laser. 
 
Equipment and solutions 
24/12 well cell culture plate   RPMI/PS/10% FBS 
Polystyrene round bottom tubes   Propidium iodide 




All handling of PI should be done under protection from light! 
Cells are incubated for the desired time, and cell suspension is transferred to 
polystyrene round bottom tubes. Propidium iodide is added, and after resuspension the 
cells are placed in the dark for 10 minutes. Then samples are analysed for red 
fluorescence (PI-staining), and the method is generally combined with forward and 
side scatter. 10 000 cells is analysed from each sample to get a statistically significant 
result. 
 
3.5 Western blot analysis – analysis of protein expression 
 
Western blot analysis is a method for detecting and quantifying specific proteins in a 
complex mixture of proteins. The protein samples are solubilised with detergents and 
reducing agents, denatured by boiling and separated electrophoretically on a 
polyacrylamide gel. After separation, the proteins are transferred to a nitrocellulose 
membrane and hybridised with antibodies that react specifically with antigenetic 
epitopes displayed by the target proteins attached to the membrane. This process is 
referred to as the Western blot. By adding a second antibody conjugated to 
horseradish peroxidase that catalyses the oxidation of luminol, the bound primary 
antibody can be detected by chemiluminescence and autoradiography. 
 
3.5.1 Preparation of cell sample for electrophoresis 
 
The cells are harvested and the proteins are solubilized by a lysis buffer. The purpose 
of this lysis is to solubelize all of the target antigens in a form that is immunoreactive 
and undegraded. Inhibitors of proteases are included in the buffer to prevent the 
release of intracellular proteases that could digest the target protein. It is important to 
keep the lysates on ice at all times to prevent protein degradation.  
 










50 mM Tris pH 8, 0     0,2 mM PMSF 
150 mM NaCl      10 µg/ml Leupeptin 
1% Triton      5 mM NaF 
0, 5% NaDeoxycholate     10 mM β-glycerophosphate 
0, 1% SDS       1 Mm Na3VO4 
0, 5% Aprotinin      In distilled water 
    
The buffer is kept on ice when in use. It is stored at -20 ˚C without aprotinin. 
 
PBS:  
Solution A: 0,2 M NaH2PO4    Solution A: 95ml 
       31,2 g NaH2PO4 x 2H2O   Solution B: 405 ml 
Distilled water to 1 litre     NaCl:          81 g 
Solution B: 0,2 M NaH2PO4    Destilled water to 5 litres 
      35,6 g NaH2PO4 x 2H2O   Adjust pH to 7,4 




Cells are collected by centrifugation and washed once with 400µl ice cold PBS. They 
are then resuspended in the appropriate amount of RIPA buffer (according to size of 
pellet), and incubated on ice for 20 minutes and votexed every 5 minutes. The cells 
are then centrifuged at 13000 rpm for 20 minutes at 4 ˚C to collect cell membranes 
and debris at the bottom of the tube. The supernatant is then transferred to a new tube, 
flash frozen in liquid N and stored  
at -70˚C. 
 
3.5.2 Determination of protein concentration 
 
The Bio-Rad assay, based on the method of Bradford (Bradford 1976) is used to 
quantitate the concentration of protein in the cell lysates. The assay depends on the 
conversion of Coomassie brilliant blue G250 in dilute acid from brownish-orange to 
an intense blue colour when binding to protein. The absorbance maximum shifts from 
465 nm to 595 nm and this is measured by using a spectrophotometer. 
 
Equipment and solutions 
Eppendorf tubes     Distilled water 
Bio-Rad protein assay    Disposable cuvettes (1, 5 ml) 
γ- globulin     Spectrophotometer 
 
Bio_rad protein assay: 
Bio-Rad protein assay and distilled water is mixed in equal amounts. 
γ- globulin: 
γ- globulin (1 mg/ml) in distilled water. 
While in use, the solution is kept on ice, and when not it use it is stored at - 20˚C. 
 
Procedure: 
A standard curve is made by dissolving 0, 5, 10, 15 and 20 µg of γ- globulin in 
distilled water to a total amount of 600 µl. The samples are prepared in parallels by 
adding 2, 5 µl of lysate to 600 µl distilled water. 400 µl Bio-Rad assay is added to all 
the standards and samples. The tubes are incubated for 10 minutes in room 
temperature before they are transferred to disposable cuvettes. The absorbance at 595 
nm is measured according to the manual. The protein concentration in the lysates are 
then estimated from the obtained standard curve. 
3.5.3 Separation of proteins by polyacrylamide gel-electrophoresis 
 
SDS-PAGE (polyacrylamide gel electrophoresis) is a technique used to separate 
molecules on the basis of their charge and size by their different migration through a 
polyacrylamide gel in an electric field. Acrylamide is the basic element in the 
polyacrylamide gel. When ammonium persulfate (APS) is added, the free radicals 
generated initiate a chain reaction that results in the formation of long chains of 
acrylamide from the initial monomers. When N,N-methylenebisacrylamide (Bis) is 
added, the chains are cross bound and this results in a gel with pore size determined 
by the length of the chains and the degree of cross binding. The amount of Bis and 
acrylamide that is chosen depends on the size of the proteins under investigation and 
the desired degree of resolution. Before loading the proteins onto the gel, they are 
denatured and dissociated by boiling the samples for 5 minutes in the strongly anionic 
detergent, SDS, in combination with the reducing agent β-mercaptoethanol. 
 The denatured polypeptides bind SDS and become negatively charged. 
 
Equipment and solutions 
Bio-Rad Mini Protean II gel apparatus  3 X SDS sample buffer 
10 % SDS polyacrylamide gel   Heat block 
Electrophoresis buffer    Syringe 
Molecular weight standard 
 
10 % SDS polyacrylamide gel: 
Separating gel:     Stacking gel: 
3, 3 ml acrylamide    1, 3 ml acrylamide 
4 ml dH2O     6, 1 ml dH2O 
2, 5 ml 1. 5 M Tris-HCl, pH 8. 8   2, 5 ml o. 5 M Tris-HCl, pH 6. 8 
100 µl 10 % SDS     100 µl 10 % SDS 
50 µl APS     50 µl APS 
5 µl TEMED     10 µl TEMED 
 
3 X SDS sample buffer:    10 X Electrophoresis buffer: 
1. 5 M Tris-HCl pH 6. 8    30 g/L Tris Base 
10 % SDS     144 g/L Glycine 
80 % Glycerol     10 g/L SDS 
β-mercaptethanol     Dissolved in distilled water 
dH2O 
Bromphenol blue     Diluted 1:10 when used 
 




Polyacrylamide gels are prepared according to the manual from Bio-Rad. For 
identification of p53, 10% separating gels are used. For preparation of samples, the 
lysate is mixed with 1/3 volume of 3 X SDS and with the addition of 1 X SDS to the 
volume of 30 µl. The samples are then boiled for 5 minutes and applied to the gel with 
a syringe. A molecular weight standard is also applied to the gel to visualize the 
migration of proteins of various sizes. The gel is run at 200 V, constant voltage, and 
the separation time depends on the size of the protein. For p53 analysis (53 kDa) the 




3.5.4 Transfer of proteins from gel to nitrocellulose membrane 
 
Most Western blot analyses are carried out by direct electrophoretic transfer of 
proteins from the gel to a nitrocellulose membrane. The membranes bind proteins 
strongly and non-specifically. In these experiments a semi-dry transfer apparatus is 
used. 
 
Equipment and solutions   Blocking solution 
Platform shaker     Semi-dry transfer cell 
Nitrocellulose membrane    Transfer buffer 
Whatman 3MM paper    Ponceau solution 
 
Transfer buffer:      Ponceau red solution: 
48 mM Tris     0, 5 g Ponceau red 
39 mM Glycine     1 ml acidic acid 
0, 0375 % SDS     100 ml dH2O 
20 % methanol 
dH2O 
 
Blocking solution:     TBS-Tween: 
8 % dried milk in TBS    TBS with 0, 1 % Tween 
 
TBS: 
20 mM Tris 
0, 8 % NaCl 
Distilled water 
 
pH is adjusted to 7, 6 with HCl. 
 
Procedure: 
When the proteins are separated on the SDS-polyacrylamide gel, the stacking gel is 
cut off, and the gel is put in transfer buffer to equilibrate. Six pieces of Whatman 
paper and one piece of nitrocellulose filter is cut at the exact size of the SDS-gel and 
soaked in the transfer buffer. 3 pieces of Whatman paper is placed in the transfer cell, 
the membrane is put on top of the papers, and the gel is put on top of the 
nitrocellulose membrane. Finally, the last 3 Whatman papers are placed on top of the 
gel. The gel and the membrane are therefore placed between the buffer-soaked filter 
paper, which serves as the ion reservoir and replaces the buffer tank. Air bubbles are 
then squeezed out by rolling a glass tube over the sandwich. It is important that the 
filter paper, membrane and gel are exactly aligned. The proteins are transferred from 
the gel to the membrane at 17 V for 25 minutes.  
 
To visualize the amount of total protein in each lane as an extra control of equal 
loading, the membrane is incubated in ponceau for 2 minutes and washed with 
distilled water. The red dye binds to the proteins and thus indicates the amount of 
protein added to each lane. The colour is then washed away with TBS-Tween before 
further processing of the membrane. The sensitivity of the Western blot analysis 
depends on reducing the background of non-specific binding by blocking potential 
binding sites with irrelevant proteins. The membrane is incubated in a blocking 
solution of 8 % milk in TBS-Tween for 45 minutes in room temperature on the 
platform shaker, or in 4 ˚C over night with gentle agitation. Excess blocking solution 
is washed away with TBS-Tween. 
 
 
3.5.5 Incubation of membrane with antibodies 
 
The proteins on the nitrocellulose membrane are hybridised in two stages. First, the 
blot is incubated with an unlabeled antibody specific to the target protein in the 
presence of blocking solution. The blot is then washed with TBS-Tween and 
incubated with anti-immunoglobulin coupled to horseradish peroxidase (HRP). After 
further washing, the antigen-antibody complex is identified by chemiluminescence 
and autoradiography. 
Equipment and solutions   TBS-Tween 
Primary antibody solution    Rock-n-roller 
Secondary antibody solution   Platform shaker 
Primary antibody solution:    Secondary antibody solution: 
1 µg/µl primary antibody in 0, 5 % milk  1:4000 secondary antibody coupled 
0, 1 % sodium azid    to horseradish peroxidase in 2% milk. 
Milk:Dried milk in TBS-Tween 
 
Procedure: 
The membrane is incubated with the primary antibody solution for 1, 5 hours in room 
temperature on the rock-n-roller or over night at 4 ˚C with gentle agitation. The blot is 
then washed 1 x 10 minutes and 2 x 5 minutes in TBS-Tween on the platform shaker 
followed by incubation with the secondary antibody solution for 45 minutes at room 
temperature. The membrane is then washed 1 x 10 min and 3 x 5 minutes in TBS-
Tween before visualisation by chemiluminescence and autoradiography. 
  
3.5.6 Detection of proteins by chemiluminescence and autoradiography 
 
The ECL Plus Western blotting detection system from Amersham Pharmacia Biotech 
provides a method for detection of immobilized antigens conjugated to HRP- labelled 
antibodies. HRP catalyses the oxidation of Lumigen PS-3 acridan substrate, 
generating thousands of acridinium ester intermediates per minute. These 
intermediates interact with peroxide under slight alkaline conditions to produce a 
sustained, high intensity chemiluminescence with maximum emission at 430 nm. 
Equipment and solutions 
Kodak X-omat 1000 processor 





ECL Plus Western blotting detection system: 
Reagent A (ECL plus substrate solution containing Tris buffer) 
Reagent B (Stock Arcidan solution in Dioxane and Ethanol) 
Reagents A and B are mixed at a ration 1:40, with 2 ml reaction fluid for each membrane. 
 
Procedure: 
The excess TBS-Tween is drained off, and the membrane is placed with the protein 
side up on a piece of glad pack. The mixture of A and B is pipetted on to the 
membrane, and the blot is incubated for 5 minutes at room temperature. Excess 
detection fluid is drained off, and the membrane is placed in a plastic wrapping inside 
a film cassette with the protein side up. A sheet of hyperfilm is placed on top of the 
membrane in a dark room, and exposed for 1-30 seconds, depending on how strong 
the signal is. The exposed film is placed inside an automatic developer, and the 








4.1 The effect of EBV on cAMP-mediated inhibition of DNA damage-induced 
apoptosis 
 
Previous work in our lab has shown that elevation of intracellular cAMP leads to G1 
arrest in normal and malignant lymphoid cells (Blomhoff et al., 1987), and  that 
cAMP also inhibits DNA replication and arrests the cells in S-phase (Naderi et al. 
2005). 
 
DNA damage responses are the basis for conventional cancer treatments like γ-
irradiation and chemotherapy, and the p53 protein is a key mediator in this process. 
Our lab has recently demonstrated that elevation of intracellular cAMP also leads to 
inhibition of DNA damage-induced apoptosis, and results so far have shown that this 
inhibition is mediated by downregulation of p53 at the level of protein stabilisation 
(Hallan Naderi et al, manuscript in preparation).Recent experiments in out lab have 
shown that EBV infection of B-cells inhibits the antiproliferative effect of cAMP 
(Kloster et al., manuscript in preparation). We therefore wished to investigate whether 
EBV-infection of normal B-cells also would influence the cAMP-mediated inhibition 
of DNA damage-induced apoptosis.  
 
To create EBV-transformed cells, we infected normal B-cells with Epstein-Barr virus.  
As a control for EBV-positive B-cells we used the lymphoid cell line Reh. These cells 
are EBV-negative cells that we for several years have used in our lab to study cAMP 
responses, and we have shown that the responses in Reh cells resemble those in 
normal B-cells. To increase intracellular levels of cAMP, we treated the cells with 
either forskolin or 8-CPT-cAMP prior to exposure to ionizing radiation. 8-CPT-cAMP 
is a membrane permeable analogue of cAMP, previously shown to activate protein 
kinase A, and forskolin is a deterpine compound isolated form plants, and it induces 
increased intracellular levels of cAMP by directly activating adenylyl cyclase 
(Seamon & Daly 1981). 
 
4.1.1 EBV-cells are more resistant γ-irradiation 
 
To induce DNA damage in the EBV-cells and Reh cells, we treated the cells with 
 γ-irradiation. By exposing the cells to increasing doses of irradiation we wished to 
analyse the dose-response. Flow cytometric analysis was carried out 24 hour after 
exposure. We have assessed apoptosis by three different methods: 1) staining the cells 
with propidium iodide (PI), 2) scatter analysis and 3) assessing subG1 DNA content.   
By staining cells with PI it is possible to distinguish between dead and viable cells 
because PI is a DNA-binding dye taken up by necrotic and late apoptotic cells. Viable 
and early apoptotic cells exclude PI because they have an intact nuclei membrane. In 
Fig.13 panel A, a typical analysis of apoptosis by PI-staining is shown. Forward 
scatter light is related to cell size while side scattered light is an indicator of the cell’s 
granularity. Apoptotic cells are smaller than viable cells, and more granular due to 
shrinkage of the cells, chromatin condensation, fragmentation of nuclei and formation 
of apoptotic bodies. Necrotic cells will be larger than viable cells due to swelling.  
Thus, by this method it is possible to separate cells into viable cells, apoptotic cells 
and necrotic cells. In Fig.13, panel B, a typical scatter analysis is shown.  
The sub-G1 method is more apoptosis-specific and relies on the fact that after DNA 
fragmentation, there are small fragments of DNA that are able to be eluted following 
washing in either PBS or a specific phosphate-citrate buffer. This means that after 
staining with a quantitative DNA-binding dye, cells that have lost DNA will take up 
less stain and will appear to the left of the G1 peak. The advantage of this method is 
that it is very rapid, detects cumulative apoptosis and is applicable to all cell 
types. However in order to be detected in the subG1 area, the cell has had to loose a 
certain level of DNA, and also cells that have lost DNA for any other reason than 
apoptosis, will appear in the subG1 region. A typical subG1 analysis is shown in 
Fig.13, panel C. 
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Figure 13: Analysis of apoptosis in Reh cells and EBV cells 24 hours after exposure of cells to 
 γ-irradiation (Gy). Analysis of apoptosis is performed by flowcytometric analysis of cells stained with 
propidioum iodide (panel A), scatter profiles (panel B) or subG1 DNA content (panel C). 
In order to induce apoptosis in cultures of Reh cells we typically irradiated the cells 
with 10Gy. As shown in Fig.14, we have induced apoptosis in approximately 70 % of 
the Reh cells 24 hours after exposure to this dosage of  γ-irradiation. However, as 
shown in Fig.15, 10 Gy of irradiation had only minor effect on apoptosis of EBV-
positive B-cells, indicating that EBV-positive B-cells are more resistant to irradiation-
induced apoptosis than are EBV-negative B-cells. In order to induce similar extent of 
apoptosis in EBV-infected cells as in Reh cells, we had to use 40-60 Gy. As shown in 
Fig.16, 60 Gy induced almost the same level of apoptosis in EBV-cells as did 40 Gy, 

































Figure 14: Reh cells were exposed to 10 Gy of γ-irradiation. Analysis was carried out 24 hours after 
exposure. The values are from one representative experiment out of three. PI indicates analysis of PI-


































Figure 15: EBV-cells were treated with forskolin (60µM) for 45 minutes and then exposed to γ-
irradiation of 10 Gy. Flow cytometric analysis was carried out after 24 hours. The values are from one 
representative experiment of three.  PI indicates analysis of cells stained with propidium iodide, SSC 
































































Figure 16: EBV-cells were exposed to γ-irradiation of 40 of 60 Gy. Flow cytometric analysis was 
carried out after 24 hours. The values are from one representative experiment of three. PI indicates 
analysis of cells stained with propidium iodide, SSC indicates scatter analysis, and subG1 indicates 




4.1.2 EBV prevents the cAMP-mediated inhibition of DNA damage-induced 
apoptosis 
 
In several papers from our lab during the last 10 years we have shown that cAMP 
inhibits proliferation of normal and malignant lymphoid cells, and we have recently 
also demonstrated that EBV infection of normal B-cell prevents this antiproliferative 
effect (Kloster et al., manuscript in preparation). Since we also recently have shown 
that cAMP inhibits DNA damage-induced apoptosis (Naderi et al, 2005), we wished 







 The cells were treated with either 8-CPT-cAMP or forskolin before exposed to DNA 
damaging γ-irradiation. As shown on figure 17, analysis of cell death 24 hours after 
exposure to ionizing radiation showed that pre-treatment of Reh cells with forskolin 
or 8-CPT-cAMP prior to irradiation markedly inhibited the DNA damage-induced 
apoptosis. This is consistent with the observations that cAMP inhibits DNA damage-
induced apoptosis in these cells. In EBV-cells, however, pre-treatment of the cells 
with forskolin or 8-CPT-cAMP prior to irradiation had only minor effect on the DNA 

























































Figure 17: Reh-cells were treated with 8-CPT-cAMP (200µM) or forskolin (60µM) for 45 minutes 
before exposure to γ-irradiation. PI-staining (PI) and scatter analysis (SSC) were performed 24 hours 
























































Figure 18: EBV-cells cells were treated with 8CPT (200µM) or forskolin (60µM) for 45 minutes 
before exposure to γ-irradiation. PI-staining (PI) - and scatter analysis (SSC) were performed 24 hours 
after exposure. The values are from one representative experiment of three.  
 
 
4.1.3 Mechanisms for how EBV prevents cAMP-mediated inhibition of DNA                      
damage-induced apoptosis. 
 
After demonstrating that EBV indeed reduces cAMP-mediated inhibition of apoptosis 
induced by γ-irradiation, we wished to unravel the mechanisms involved. As indicated 
from recent results in our lab, cAMP inhibits DNA damage-induced apoptosis by 
down-regulation of p53 levels (Hallan Naderi et al., manuscript in preparation). To 
investigate the mechanisms whereby EBV renders the cells resistant to cAMP-
mediated inhibition of apoptosis, we therefore investigated the effect of EBV on DNA 
damage checkpoints – including p53 levels. The cells were treated in the same manner 
as described in legends to figures 17 and 18, and the lysates were subjected to 
Western blot analysis of p53-levels and proteins involved in checkpoint-control. 
 
As shown in Fig.19, γ-irradiation induced p53-stabilization as demonstrated by 
enhanced p53 levels and phosphorylation of p53 at Ser 15 in both Reh cells and in 
EBV-cells. In Reh cells, elevation of cAMP-levels by 8-CPT-cAMP markedly 
reduced this induced stabilization of p53, whereas in EBV-cells 8-CPT-cAMP was 
not able to reduce this stabilization. These results were in accordance with the 
inability of cAMP to prevent DNA damage-induced apoptosis in EBV-cells (see 
Fig.18).    
  
In fig.20 are presented the similar results from forskolin-treated cells. Thus, again no 
inhibitory effect of cAMP was noted on p53 levels and stabilization of p53 
(represented by enhanced phosphorylation of p53 at Ser 20) in EBV-cells, whereas 
both total levels of p53 and phosphorylation of p53 at Ser 20 were markedly reduced 





















Figure 19: Effect of 8CPT-cAMP and γ-irradiation on p53 levels and p53 stabilization. EBV-cells 
and Reh cells were incubated with 8-CPT-cAMP (200µM) for 45 minutes prior to exposure to 
 γ-irradiation. The cells were harvested 4 hours after irradiation, and equal amounts of protein (65µg) 
were separated on a 10% polyacrylamide gel before performing Western blot analysis using antibodies 
against p53 (total) and p53(S15). For visualization of loading the blot was rehybridized with antibodies 
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Figure 20: Effects of forskolin and γ-irradiation on p53 levels and p53 stabilization.  EBV-cells 
and Reh cells were incubated with forskolin (60µM) for 45 minutes prior to exposure to γ-irradiation. 
The cells were harvested 4 hours after irradiation, and equal amounts of protein (65µg) were separated 
on a 10% polyacrylamide gel before performing Western blot analysis using antibodies against p53 
(total) and p53 (S20).  For visualization of loading the blot was rehybridized with antibodies against 
actin. One representative experiment of three is shown. 
 
 
The upstream regulators of p53 are the checkpoint control proteins Chk1 and Chk2, 
both known to phosphorylate and thereby stabilize and activate p53. Active Chk1 and 
Chk2 are detected by antibodies against Chk1 phosphorylated at Ser317 or Ser345, or 
against Chk2 phosphorylated at Thr68, respectively. As shown in Fig.21, irradiation 
induced activation of both Chk1 and Chk2, but elevation of cAMP did not prevent this 
activation in either Reh cells or in EBV-cells. Thus, we could conclude that EBV-
infection does not affect checkpoint-control upstream of p53, and cAMP-mediated 

















Figure 21: Effect of forskolin and γ-irradiation on DNA damage-induced checkpoint. Reh or  
EBV- cells were incubated with forskolin (60µM) for 45 minutes and exposed to γ-irradiation. The 
cells were harvested 4 hours after irradiation, and equal amounts of protein (65µg) were separated on a 
10% polyacrylamide gel before performing Western blot analysis using antibodies against Chk1 
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5.1 EBV inhibits the effect of cAMP on DNA damage-mediated apoptosis 
 
Epstein-Barr virus is a DNA tumour virus involved in development of certain B-cell 
and epithelial cell malignancies. Several years ago our lab showed that EBV-
transformed B-cells were no longer inhibited by TGFβ (Blomhoff et al., 1987). 
Recently, we have shown that EBV infection of normal B-lymphocytes also inhibits 
the antiproliferative effect of cAMP in these cells, and it seems as though cAMP in 
EBV-transformed B-cells can no longer induce G1 arrest or inhibit S-phase 
progression (Kloster et al, manuscript in preparation).  
 
The aims of this paper were to investigate whether EBV-infection of B-cells 
influences cAMP-mediated regulation of DNA damage-induced apoptosis triggered 
by γ-irradiation and, if so, to establish the mechanisms involved. As a control for 
EBV-positive B-cells we used the cell line Reh. Reh cells are EBV-negative cells that 
we for several years have used in our lab to study cAMP responses, and we have 
shown that the responses in Reh cells resemble those in normal B-cells. Thus, we 
have shown that cAMP leads to G1 arrest and inhibition of S-phase progression in 
Reh cells as well as in normal B-cells (Blomhoff et al., 1988; Naderi et al., 2005), and 
in both cell types the growth arrest includes downregulation of cyclin D3 (Naderi et 
al., 2000; Naderi et al., 2004) and Myc (Blomhoff et al., 1987). Taken together, we 
believe that Reh cells is a good model for EBV-negative B-cells to use as a control in 
our experiments. 
 
Our experiments showed that EBV-transformed B-cells were more resistant to 
 γ-irradiation, and needed larger doses than the Reh cell line to induce apoptosis. 
Further, we showed that EBV prevents the cAMP-mediated inhibition of apoptosis 
initiated by ionizing radiation. Results in our lab have shown that cAMP inhibits 
DNA damage induced apoptosis by downregulation of p53 at the level of protein 
stabilisation (Hallan Naderi et al., manuscript in preparation). To investigate the 
mechanisms whereby EBV render the cells resistant to cAMP-mediated inhibition of 
DNA damage-induced apoptosis, we therefore investigated the effect of EBV on the 
DNA damage checkpoint – including p53.  
 
In this experiment, we showed that ionizing radiation activates p53 in both Reh and 
EBV-cells demonstrated by enhanced stabilisation of p53. Further, we showed that in 
Reh cells treated with forskolin or 8-CPT-cAMP and subsequently exposed to γ-
irradiation, p53 stabilisation was inhibited. In EBV cells treated with the same agents 
there was little or no downregulation of p53, consistent with our results that EBV 
prevents the inhibitory effect of cAMP in response to DNA damage induced by 
ionizing radiation. To unravel whether EBV-transformation affected the checkpoint-
control upstream of p53, we investigated the regulation of Chk1 and Chk2. We 
showed that activation of Chk1 and Chk2 were equally regulated in both Reh and 
EBV cells, suggesting that the inhibitory effect of EBV on cAMP-mediated regulation 
of DNA-damage-induced apoptosis is not mediated via checkpoint-control upstream 




Work by O’Nions and Allday (2003) has shown that after exposure to the cytotoxic 
drug cisplatin, EBV disrupts the G1 checkpoint, but has no effect on p53 activation.  
Further, their work indicated that EBV acts downstream of p53 by blocking p21
(Cip1) 
accumulation, leading to continuous activation of Cdk2, maintenance of pRB 
hyperphosphorylation and replication of DNA. In the same paper, they demonstrated 
that γ –irradiation could induce cell cycle arrest in EBV cells, and that this correlated 
with inhibition of Cdk2 activity. As reported by Cannel and coworkers (1996; 1998), 
EBV-positive cells that respond to cisplatin with reduced expression of p21
(Cip1)
, 
respond to irradiation by increased levels of p53 and p21
(Cip1)
. This indicates that 
cisplatin and γ –irradiation triggers different signals in EBV-infected cells, and that 
latency functions of EBV must discriminate between these. Recently, O’Nions and 
coworkers (2006), released further results showing that when proliferating B-
lymphocytes respond to γ –irradiation, p21
(Cip1)
 protein accumulates and the cells 
undergo cell cycle arrest irrespective of whether EBV is present or not, and that the 
phosphorylation, stabilization and activation of p53 appear to be unaffected by EBV. 
This correlates with our results that EBV does not act upstream of p53 in response to 
double stranded DNA damage. 
 
In the same publication by O’Nions and coworkes  (2006) it was shown that EBV 
cells tend to accumulate in the G1 and G2 phases of the cell cycle when treated with 
ionizing radiation. In our experiments, however, the lymphocytes respond to  
γ –irradiation mainly by apoptosis. This could be related to the dosage used. O’Nions 
and coworkers used a dosage of 8, 5 Gy in their experiments, whereas in our work we 
used 40 Gy to induce DNA damage-induced apoptosis.  
 
The mechanism behind the increased resistance to DNA damage-induced apoptosis in 
EBV cells is not fully known. In 1998, Komano and coworkers showed that EBV-
positive cells were more resistant to apoptosis than were EBV-negative cells, and that 
EBV-infected cells expressed the Bcl-2 protein through which cells might become 
resistant to apoptosis. This was the first report that Burkitt’s lymphoma type EBV-
infection confers apoptosis resistance even in the absence of LMP1 or BHRF1 – both 
which are known to have an antiapoptotic function. The EBV protein BHRF1(Bam HI 
fragment H rightward open reading frame 1) shares a distant collinear amino acid 
sequence homology with the protein coded by the Bcl-2 protooncogene, and can 
protect against apoptosis induced by the DNA damaging agents cisplatin, etoposide 
and mitomycin C (Tarodi et al., 1994). It has been shown that transfection with the 
EBV genes LMP1 or EBNA2 upregulates Bcl-2 in B-cell lines, indicating a role of 
this anti-apoptotic protein in EBV-protection against apoptosis. In fact, Roth and 
coworkers (1996) have shown that LMP expression also provides resistance against 
hydrocortisone-induced apoptosis, and that this resistance possible is due to 










Another study shows that EBV-negative Burkitt lymphoma-derived cell line, BL41 
are extremely sensitive to genotoxic drugs, and rapidly undergo apoptosis, whereas 
latent infection with EBV protects these cells from both apoptosis and cell cycle arrest 
(Wade and Allday, 2000). Interestingly, it seemed as though LMP1 was not involved 
in this protection, and that levels of Bcl-2 and related proteins did not change 
significantly during apoptosis, nor was the level of the anti- or proapoptotic proteins 
predictive of the outcome of the treatment .Recently, Clybouw and coworkes (2005) 
showed that EBV infection leads to post-transcriptional downregulation of expression 
of the proapoptotic protein Bim, and that EBV-mediated resistance to growth factor 
deprivation in human B-lymphocytes is dependent on BimEL expression, indicating a 
contribution to the oncogenic potential of EBV. 
 
It would be interesting to investigate which EBV-genes inhibit the cAMP-mediated 
response. LMP1 is shown to be important in EBV-mediated B-cell proliferation and 
mimics an activated CD40 receptor, and thereby the CD40/CD40L interaction 
between B-cells and other cells in the immune system (Uchida et al., 1999; Lam and 
Sugden, 2002; Panagopopoulos el al., 2004). However, we have shown in our lab that 
CD40/IL-4 mediated regulation of normal B-cells do not counteract cAMP-mediated 
growth inhibition (Kloster et al., manuscript in preparation).  
 
The mechanisms by which EBV inhibits the effects of cAMP on growth arrest and 
apoptosis are currently a subject of investigation in our lab. The level of inhibition 
could theoretically be upstream of p53 in the DNA damage pathway, in the synthesis 
or function of cAMP or in the cAMP pathway. Recent experiments in our lab indicate 
that EBV-infection of B-cells inhibits adenylyl cyclase activation and cAMP 
accumulation (Kloster et al., manuscript in preparation), and this fits with our results 
demonstrating that EBV-infection renders the B-cells irresponsive to the cAMP-
mediated destabilization of p53, and that it does not affect the checkpoint-control 
upstream of p53.  
 
5.2 Clinical implications of our results 
 
Normal cell growth is dependent on a fine tuned balance between positive and 
negative growth signals, and a balance between cell proliferation and programmed 
cell death. Any changes in these processes may lead to cancer development, and the 
disruption of DNA damage checkpoint (ATM-Chk2-p53) and/or the intrinsic pathway 
of the apoptosis machinery are both very common in cancer cells (Shin et al., 2006; 
Soung et al., 2006; Ishikawa et al., 2006). Cancer rises as a result of a multistep 
accumulation of genetic changes that can occur in tumour suppressor genes and/or 
oncogenes. These changes do not only facilitate tumour formation, but can also 









DNA damage responses are the basis for conventional cancer treatments like γ-
irradiation and chemotherapy, and the p53 protein is a key mediator of the ATM-
dependent DNA damage response cascade following cellular exposure to ionizing 
radiation (for a review, see Cuddihy and Bristow, 2004; Choudhury et al., 2006 ). By 
inducing DNA damage in the cancer cells, the cells are either marked for apoptosis or 
arrested at different stages in the cell cycle. The general response of lymphoid cells to 
DNA damage is apoptosis. A major problem with conventional cancer therapy is that 
usually only a subgroup of patients responds to the treatment given. In addition, side 
effects of cancer treatment limit the dose-efficiency of the treatment. In future 
research and development of new cancer treatments, the aim must be to create 
combinational regimes with higher efficacy and lower dose requirements so that more 
patients will respond with fewer side effects. 
 
Many tumours express high levels of cAMP or cox-2 (induces PGE2-mediated 
induction of cAMP) (Gunnarson et al., 2006). Previously we have shown in our lab 
that elevation of intracellular cAMP leads to G1 arrest in normal and malignant 
lymphoid cells (Blomhoff et al., 1987). We have recently demonstrated that elevation 
of intracellular levels of cAMP also inhibits DNA replication and arrests the cells in 
S-phase (Naderi et al., 2005). A number of current cancer therapy regimes rely on the 
use of drugs whose cytotoxic activity depend on ongoing DNA replication. Elevation 
of intracellular cAMP prior to irradiation or chemotherapy has recently been shown to 
inhibit DNA damage induced-apoptosis (Naderi et al., 2005), rendering tumours 
expressing high levels of cAMP resistant to this antitumour treatment. This leads to 
the possibility of using cAMP antagonists/PKA inhibitors or cox2-inhibitors prior to 
conventional therapy to increase the effect of γ-irradiation or chemotherapy in 
tumours expressing high cAMP levels and thereby improving the dose-efficiency of 
the treatment. This is at present the subject for further research in our lab. Of note is 
that a recent paper demonstrated induced apoptosis of neuroblastoma cells treated 
with a combination of cox-2 inhibitors and low doses of the cytotoxic agents 
doxorubicin or etoposide (Lau et al., 2006). The authors did not, however, relate the 
cox-2 inhibition to inhibition of cAMP levels. 
 
Epstein-Barr virus is a DNA tumour virus belonging to the γ-herpes virus family.  
More than 90% of the adult population is seoropositive for EBV as a result of an 
asymptomatic primary infection in the childhood. Like all herpes viruses, EBV is able 
to persist in the host for life, but in the majority of healthy carriers the virus causes no 
disease. This is because a delicate balance between the host immune system and the 
virus is maintained. Acute EBV-infection in the adult can cause infectious 
mononucleosis (IM), characterized by the triad of fever, lymphadenopathy and 
pharyngitis (Papesch & Watkins, 2001). EBV is also shown to cause different types of 
cancer and proliferative disorders including Burkitt’s lymphoma (Epstein et al., 1964), 
nasopharyngeal carcinoma (Henle & Henle, 1976), gastric cancer (Osato & Imai, 
1996), Hodgkin’s lymphoma (Deacon et al, 1993), post-transplant 






We have shown that cAMP inhibits DNA damage induced-apoptosis and that EBV 
prevents this inhibition, rendering the cells resistant to cAMP inhibition. In clinical 
practice, this means that patients with EBV-positive malignancies may not benefit 
from a combinational treatment of PKA inhibitors and irradiation/chemotherapy as 
postulated for normal B-cells - even in tumours expressing high levels of cAMP. 
Because the antiproliferative effect of cAMP is neutralized in EBV-cells, one would 
expect that EBV-positive cancers are more susceptible to cytotoxic agents. However, 
this is shown by ourselves and by others (Clybouw et al., 2005) not to be the case. In 
fact, we have shown that EBV-cells are more resistant than EBV-negative cells to 
DNA damage induced-apoptosis. This may indicate that patients with EBV-positive 
malignancies need higher doses of treatment to respond to conventional treatment. 
And, as EBV not only infects B-cells, but also T-cells and epithelial cells, these 
results may have implications in other types of cancers as well.  
 
EBV has recently been shown in our lab to exert its inhibitory effect on cAMP-
mediated G1-arrest at the level of adenylyl cyclase (Kloster et al., manuscript in 
preparation), and further unravelling the mechanisms by which EBV brings out its 
inhibitory effects on the ability of cAMP to prevent apoptosis in response to DNA 
damage, is a promising area of further research in our lab. Hopefully this research will 
provide us with some novel tools to improve antitumour treatment of EBV-positive 




Our aims for the current project were to unravel whether EBV-infection of normal B-
cells prevents the cAMP-mediated inhibition of DNA damage-induced apoptosis in 
response to γ-irradiation, and if so, to establish the mechanisms involved. 
 
We could conclude that:  
 
1) EBV-transformed B-cells are more resistant to DNA damage-induced 
apoptosis, and that higher doses of γ-irradiation are required to trigger an 
apoptotic response. 
 
2) EBV inhibits the cAMP-mediated regulation of DNA damage-induced 
apoptosis triggered by γ-irradiation.  
 
3) The mechanism by which EBV regulates cAMP inhibition of apoptosis when 
exposed to ionizing radiation does not seem to involve the DNA damage 
checkpoint- control upstream of p53 but rather affect the cAMP-mediated 
pathways as such. Thus, EBV-infection prevents cAMP-mediated 
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